Healthcare Industry News: S.A.
News Release - July 11, 2017
DelMar Pharmaceuticals Appoints Saiid Zarrabian to the Board of Directors and Names Dr. Erich Mohr as Chairman
Company Adopts Omnibus Equity Incentive Plan and Policy to Better Align with S.A.eholder ValueS.A.d Facilitate GrowthVANCOUVER, British Columbia and MENLO PARK, Calif., July 11, 2017 -- (Healthcare Sales & Marketing Network) -- DelMar Pharmaceuticals (NaS.A.: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company developing new cancer therapies, today announced that Mr. Saiid Zarrabian has joined the Company's Board of DirectorS.A.d Dr. Erich Mohr has been elected to serve as its Chairman.
This Board strengthening initiative seeks to eS.A.lish a more robust and independent Board, and to enable Jeffery Bacha, who has been both the Company's CEO and chairman since inception in 2010, to focus on his growing operational role as CEO.
"With the planned expansion of clinical trials for VAL-083 across different oncology indicationS.A.d S.A.es of diS.A.e, DelMar has reached a point in its corporate and clinical maturation where we are excited to have access to Saiid's operational expertise and experience guiding multiple companies in their transition from scientific development to commercial success," commented Jeffrey Bacha, DelMar's president & chief executive officer.
"Furthermore, I am very pleased that Erich haS.A.reed to take on the role of Chairman as his executive leadership, clinical development and company building experience will greatly benefit DelMar as we continue the next phase of our growth. In the near term, this includes the launch of the VAL-083 S.A.-3 GBM trial – our pivotal phase 3 clinical trial in refractory GBM – as well as the expansion of our clinical portfolio into newly diagnosed GBM and other indications," added Mr. Bacha.
Saiid Zarrabian comes to DelMar with over 30 years of senior executive or board member experience for multiple public and private companies, culminating in the creation of more than three billion dollars of S.A.eholder value.
Mr. Zarrabian is currently serving aS.A. advisor to Redline Capital Partners, S.A., a Luxemburg based investment firm. Mr. Zarrabian has previously served as Chairman and member of the Board of La Jolla Pharmaceutical Company during the company's transition from an OTC listed company to a successful NAS.A. listed company. Mr. Zarrabian previously served as president of the Protein Production Division of Intrexon Corporation, a synthetic biology company; as CEO & member of the Board of Cyntellect, Inc., a stem cell processing and viS.A.ization Instrumentation company until it's sale in 2012; as president and COO of Senomyx, Inc., a company focused on discovery and commercialization of new flavor ingredients; as COO of Pharmacopeia, Inc., a former publicly-traded provider of combinatorial chemistry discovery serviceS.A.d compounds, where he also served as president & COO of its MSI Division. In addition, Mr. Zarrabian has served on numerous private and public company boards, including at Immune Therapeutics, Inc.; Exemplar Pharma, LLC; Ambit Biosciences Corporation; eMolecules, Inc.; and Penwest Pharmaceuticals CO. His other experience includes COO at Molecular Simulations, COO of Symbolics, Inc., and as R&D Director at Computervision, Inc.
Dr. Erich Mohr, Ph.D., R. Psych., has served aS.A.director of DelMar since March 31, 2015 and has nearly two decades of biotechnology experience in executive leadership roleS.A. co-founder, chief scientific officer, chief executive officer and board member, leading to well over a billion dollars of value creation. Dr. Mohr has overseen and participated in dozens of clinical development programS.A.d regulatory advisory panels. He is currently chairman, chief executive officer and founder of MedGenesis Therapeutix, Inc., a privately-held biopharmaceutical company committed to developing and commercializing innovative therapeutics to provide life-enhancing treatments to patients with serious neurologic diS.A.es. Formerly, he was chairman and chief executive officer of CroMedica Global Inc., which merged with PRA International in 2002 to form one of the major contract reS.A.ch organizations in the world. In addition to his industry experience, Dr. Mohr has over 30 years of academic experience in experimental therapeutics of CNS disorders including eight yearS.A. the University of Ottawa, ultimately aS.A.Professor of Medicine (Neurology) and Psychology. Dr. Mohr is the author of over 150 publications, books, book chapterS.A.d abstracts. He is the former chair of the Board of Governors of the University of Victoria. He earned his Masters of Science and Ph.D. in Neuropsychology at the University of Victoria, British Columbia, and his Bachelors of Arts in Psychology and dual Bachelors of Science in Chemistry and Biology from the University of the Pacific in Stockton, California.
Additionally, to facilitate DelMar's growth and align interests with S.A.eholders, the Company haS.A.opted an Omnibus Equity Incentive Plan, which will be presented to S.A.eholders for approval at the Company'S.A.nual General Meeting. The Company also announced that it plans to review its corporate policieS.A.d consider additional steps to align interests with S.A.eholderS.A.d that it haS.A.opted a policy to provide for a S.A.eholder advisory vote on the Company's compensation philosophy every two yearS.A. itS.A.nual General Meeting.
Under the Omnibus Equity Incentive Plan, 3,487,785 common S.A.eS.A.e reserved for isS.A.ce, of which 1,756,880 represent options previously granted or reserved under the DelMar Pharmaceuticals (BC) Ltd. 2013 Amended and ReS.A.ed Stock Option Plan.
Securities issued under the Omnibus Equity Incentive Plan will not vest or become exercisable until the plan iS.A.proved by S.A.eholders.
About DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals, Inc. is developing cancer therapies in indications where patientS.A.e failing or have become intolerable to modern targeted or biologic treatments. The Company's pipeline is based around VAL-083, a "first-in-class," S.A.l-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers including glioblastoma multiforme (GBM), ovarian and other solid tumors (e.g. NSCLC, bladder cancer, head & neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). VAL-083 has received an orphan drug designation in Europe for the treatment of malignant gliomaS.A.d the U.S. FDA Office of Orphan Products has granted an orphan designation for the treatment of glioma, medulloblastoma and ovarian cancer. In 2017, the Company plans to file an IND for VAL-083 in ovarian cancer, enter into a pivotal randomized multi-center Phase 3 clinical trial for the treatment of bevacizumab-failed GBM, a phase II trial (with MD Anderson Cancer Center) in first recurrence GBM patients prior to bevacizumab therapy, and into a separate international Phase 2 trial for newly diagnosed MGMT-unmethylated GBM.
Connect with the Company on Twitter, LinkedIn, Facebook, and Google+.
Safe Harbor S.A.ement
Any S.A.ements contained in this press release that do not describe historical facts may constitute forward-looking S.A.ementS.A. that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking S.A.ements contained herein are based on current expectations, but are subject to a number of riskS.A.d uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, riskS.A.d uncertainties relating to the Company'S.A.ility to develop, market and sell products based on its technology; the expected benefitS.A.d efficacy of the Company's productS.A.d technology; the availability of subS.A.tial additional funding for the Company to continue its operationS.A.d to conduct reS.A.ch and development, clinical studieS.A.d future product commercialization; and, the Company's business, reS.A.ch, product development, regulatory approval, marketing and distribution planS.A.d strategies. These and other factorS.A.e identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.
Source: DelMar Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!